Merck’s Pepcid (famotidine)
Approved Dec. 10 for "short-term treatment of patients with symptoms" of gastroesophageal reflux disease (GERD) and for "short- term treatment of esophagitis due to GERD, including erosive or ulcerative disease diagnosed by endoscopy." SmithKline Beecham's Tagamet (cimetidine) is indicated for "erosive esophagitis diagnosed by endoscopy" with treatment indicated for "12 weeks for healing of lesion and control of symptoms." Glaxo's Zantac (ranitidine) is indicated for the treatment of GERD with "symptomatic relief commonly" occurring one or two weeks after therapy commences. Pepcid's dosage for GERD is 20 mg b.i.d for up to six weeks. For patients with esophagitis and accompanying GERD symptoms, dosing is "20 or 40 mg b.i.d. for up to 12 weeks." Merck filed for the supplemental indication on May 24, 1989....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth